Skip to content

Released Aug 6, 2018, after the close

10-Q filed Aug 6, 2018, 37 days after period end · 0001564590-18-019456

Q2 2018 · 10-Q
Revenue$1.03M+0.1% vs Q2 2017+0.1% vs Q1 2018
Net Income-$19.65MN/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.37N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$19,605,000N/M
Operating Cash Flowderived-$11,523,000N/M
Free Cash Flowderived-$11,801,000N/M
Margins · derived
Operating margin-1909.0%−976.2 pt vs Q2 2017
Net margin-1913.7%−973.7 pt vs Q2 2017

What the release said

The release

Same quarter

MetricQ2 2018Q2 2017Q2 2016Q2 2015
Revenue$1.03M$1.03M$1.03M$329.00K
Net Income-$19.65M-$9.65M-$8.41M-$7.78M
EPS Diluted-$0.37-$0.23-$0.29-$0.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR